<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056095</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000271936</org_study_id>
    <secondary_id>FRE-FNCLCC-GETUG-11/0105</secondary_id>
    <secondary_id>EU-20234</secondary_id>
    <nct_id>NCT00056095</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may
      allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

      PURPOSE: This phase II trial is studying how well allogeneic stem cell transplant works in
      treating patients with metastatic kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the 18-month survival rate of patients with metastatic renal cell carcinoma
           treated with allogeneic stem cell transplantation.

        -  Determine the objective rate of response of patients treated with this regimen.

        -  Determine post-transplant immunological reactions and recuperation of patients treated
           with this regimen.

        -  Determine the antitumoral activity of this regimen in these patients.

      OUTLINE: This is a non-randomized, multicenter study. Patients are assigned to 1 of 2
      treatment groups based on availability of a compatible family member for stem cell
      transplantation.

        -  Group I: Patients with a compatible family donor receive conditioning chemotherapy
           comprising cyclophosphamide IV over 2 hours on days -7 and -6 and fludarabine IV once
           daily on days -5 to -1. Patients undergo filgrastim (G-CSF)-mobilized allogeneic stem
           cell transplantation on day 0. Patients also receive immunosuppression therapy with
           cyclosporine beginning on day -2. Patients who have persistent or progressive disease,
           mixed chimerism, and no evidence of grade 2 or greater graft-vs-host disease, and have
           been off immunosuppression therapy for 1-2 weeks receive donor lymphocyte infusion on
           days 7 and 21.

        -  Group II: Patients without a compatible family donor receive treatment (immunotherapy,
           vaccination therapy, or chemotherapy) at the discretion of the treating physician.

      Patients are followed every 3 months for 5 years.

      PROJECTED ACCRUAL: A total of 170 patients (60 patients for group I and 110 patients for
      group II) will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2002</start_date>
  <completion_date type="Actual">February 13, 2008</completion_date>
  <primary_completion_date type="Actual">February 13, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate at 18 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective rate of response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-transplant immunological reactions and recuperation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumoral activity</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allograft (compatible non-family member)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
    <arm_group_label>Allograft (compatible non-family member)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Allograft (compatible family member)</arm_group_label>
    <arm_group_label>Allograft (compatible non-family member)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic renal cell carcinoma

          -  No sarcomatoid, pure papillary, or Bellini renal cell cancer

          -  Measurable and/or evaluable disease

          -  Disease progression after at least 1 immunotherapy regimen for metastatic disease

          -  Localized metastases allowed provided the following are true:

               -  At least 3 months since prior treatment for metastases

               -  Not considered likely to influence outcome of transplantation

          -  No brain metastases unless treated surgically or radiologically and MRI normal

          -  Sufficiently healthy, HLA-compatible family member must be available as donor for
             patients undergoing stem cell transplantation

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 65

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  More than 6 months

        Hematopoietic

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Transaminases less than 1.5 times upper limit of normal (ULN)*

          -  Bilirubin less than 1.5 times ULN* NOTE: *Unless due to Gilbert's disease

        Renal

          -  No renal insufficiency

          -  Calcium less than 10.4 mg/dL

          -  Creatinine clearance greater than 50 mL/min

        Cardiovascular

          -  Ejection fraction greater than 50%

        Pulmonary

          -  No DLCO that would preclude fludarabine or busulfan therapy

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No physical obstacle to receiving study treatment

          -  No known autoimmune disease

          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No uncontrolled bacterial, viral, or fungal infection

          -  No prior or concurrent psychiatric disease

          -  HIV negative

          -  HTLV1 negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  No tolerance to fludarabine and busulfan

        Endocrine therapy

          -  No concurrent corticosteroids

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Blaise, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu-Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lapeyronie-CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Archet CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Brabois</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

